In today's Episode Rewind we're revisiting our interview with Dr. Marcela Smid, live at the 56th Annual ASAM Conference in Denver. Dr. Smid sits down to discuss article submissions and peer review, as well as demystifying the scientific publishing process for new authors.

Learn more about this year's upcoming conference in San Diego, CA > https://bit.ly/3OTOx79 

In this episode of Beyond The Abstract, Dr. Matthew Sloan sits down to discuss findings from his recent article Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine featured in the November/December issue of the Journal of Addiction Medicine. Join us as Dr. Sloan shares insights into his study investigating the feasibility of delivering symptom-triggered alcohol withdrawal management over telemedicine.

Dr. Matthew Sloan is a clinician scientist at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada. He specializes in the treatment of substance use disorders and their psychiatric comorbidities. He completed medical school and psychiatry residency at McGill University followed by a postdoctoral fellowship in human psychopharmacology at the National Institutes of Health and an addiction psychiatry fellowship at Yale University. Dr. Sloan's primary research interests are developing innovative new treatments for substance use disorders and exploring determinants of psychopharmacological response to drugs of misuse. He has obtained competitive research funding from the Canadian Institutes of Health Research, Health Canada, and the Centre for Addiction and Mental Health Discovery Fund and has received scientific prizes from the American Academy of Addiction Psychiatry and the National Institute on Alcohol Abuse and Alcoholism.

Article Link: Symptom-Triggered Alcohol Withdrawal Management Delivered Over Telemedicine

In this episode, Dr. Nicolas Garel joins the podcast to discuss findings from his new article in the September/October issue of the Journal of Addiction Medicine titled Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study.

Dr. Nicolas Garel is a psychiatrist and clinician-scientist at the Centre Hospitalier de l’Université de Montréal (CHUM). He is an assistant professor in the Department of Psychiatry at the Université de Montréal and adjunct professor in the Department of Psychiatry and Behavioral Sciences at Stanford University. Dr. Garel completed his medical degree at the Université de Montréal, followed by his psychiatry residency and clinician-scientist fellowship at McGill University, and later pursued advanced training in research and addiction medicine at Stanford University. His research program focuses on innovative interventions for treatment-resistant mood disorders and substance use disorders.

Article Link: Increased Risks of Major Cardiac Adverse Events in Stimulant Use Disorder as Compared With Other Substance Use Disorders: A Propensity-score Matching Cohort Study

In this episode, Dr. Blythe Bynum joins the show to discuss her new article titled Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder, featured in the November/December issue of the Journal of Addiction Medicine.

Dr. Blythe Bynum is an assistant professor in the Department of Obstetrics and Gynecology at Thomas Jefferson University in Philadelphia, Pennsylvania. She is a board certified OBGYN with fellowship training in Complex Family Planning. 

Article Link: Navigating Choices: Pregnancy Options Counseling Experiences in Individuals With Opioid Use Disorder

In this episode, Dr. Bradley Stein joins the show to discuss findings from his new study titled Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes, featured in the September/October issue of the Journal of Addiction Medicine.

Dr. Bradley Stein is a practicing physician and senior physician policy researcher at RAND. His research career has focused on improving access to, quality of, and outcomes from care of individuals with mental health and substance use disorders being treated in community settings. For two decades, Dr. Stein has studied the opioid crisis, serving as principal investigator for numerous federally and privately funded studies. He has published multiple peer-reviewed articles related to studies of opioid use disorder treatment, harm reduction, and the effects of state and federal policies, and he has provided Congressional testimony related to his research on multiple occasions. And his work has been covered by a range of media outlets including the Economist, Washington Post, and New York Times.

Article Link: Medicaid Unwinding: Association With New and Ending Buprenorphine Treatment Episodes

Guest Editorial: Medicaid Unwinding May Have Substantially Disrupted Buprenorphine Treatment

In this episode, Dr. Vinit Patel sits down to discuss his new article Non-medical Mephentermine Use: A Systematic Review of Literature, as well as what exactly mephentermine is, why and how it is currently being used in non-medical settings specifically in India and South Asia, and some of the contributing factors associated with geographic disparities in non-medical mephentermine use.

Article Link: Non-medical Mephentermine Use: A Systematic Review of Literature

Dr. Jennifer McNeely stops by the show to discuss her new article Medication for Opioid Use Disorder for Hospitalized Patients at Six New York City Public Hospitals with an Addiction Consult Service.

Article Link: Medication for Opioid Use Disorder for Hospitalized Patients at Six New York City Public Hospitals with an Addiction Consult Service

Dr. Pouya Azar stops by the show to talk about his recent article Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative. He discusses the potential benefits of transitioning patients with opioid use disorder from traditional to extended-release or long-acting buprenorphine within 7 days or 24 hours, respectively, of treatment, as well as challenges and future questions that arose from his narrative review.

Pouya Azar, MD, FRCPC, DABAM, is a clinician-scientist in addiction psychiatry and pain medicine based in Vancouver, British Columbia, Canada. He serves as co-medical manager of the Complex Pain and Addiction Service (CPAS) at Vancouver Coastal Health, a consult service providing management of pain, mental health disorders, and substance use disorders across Vancouver General Hospital, the University of British Columbia (UBC) Hospital, and GF Strong Rehabilitation Centre. He is also an assistant professor (tenure-track) in the UBC Department of Psychiatry, research scientist co-lead of the Substance Use Disorder Clinical Research Unit at the BC Centre for Excellence in HIV/AIDS, and a physician at the Vancouver General Hospital Transitional Pain Clinic. Dr. Azar’s clinical and translational research focuses on developing novel opioid agonist treatment initiation and withdrawal management protocols, medical devices, digital health apps, and prevention programs to improve patient outcomes.

-

Article Link: Transition to Extended-release Buprenorphine Injectable Within Seven Days for Opioid Use Disorder Treatment: A Scoping Narrative

Host Dr. Shawn McNeil is joined by Dr. Robert Sherrick to discuss his new article Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs featured in the July/August issue of the Journal of Addiction Medicine.

Robert Sherrick, MD, DFASAM, is chief science officer for Community Medical Services, a company that serves patients through over 70 Opioid Treatment Programs in 12 states. He also has experience working at an inpatient addiction treatment facility, Pathways Treatment Center, treating all forms of substance use disorders and dual diagnosis patients.

Dr. Sherrick has been providing medication treatment for opioid use disorder since 2003, initially in an office setting using buprenorphine and subsequently with methadone in Opioid Treatment Programs. He established a state-wide buprenorphine treatment program for VA Montana with extensive use of telemedicine. He is board certified in internal medicine and addiction medicine through the American Board of Preventive Medicine. He is past president of the Northwest Chapter of the American Society of Addiction Medicine (ASAM).

-

Article: Relationship Between Methadone Induction Dosing and Retention in Treatment in Opioid Treatment Programs

Dr. Emily Pasman stops by the show to talk about her recent article Nonabstinence Among US Adults in Recovery From an Alcohol or Other Drug Problem. She discusses the findings from her study as well as the potential limitations of using a solely abstinence-focused treatment and recovery model for addiction care.

Emily Pasman is a licensed social worker and postdoctoral research fellow at the University of Michigan Center for the Study of Drugs, Alcohol, Smoking, and Health. Her research aims to improve health equity for people who use drugs by expanding harm reduction interventions; supporting affected family members; and addressing disparities in service access, uptake, and outcomes. Grounded in her practice background in peer-delivered services, she uses participatory methods to engage people with lived and living experience in all aspects of the research process.

-

Article Link: Nonabstinence Among US Adults in Recovery From an Alcohol or Other Drug Problem